News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Epigenomics AG  / Key word(s): Capital Increase

07.11.2016 18:50

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Publication of Inside Information according to Article 17 MAR

Epigenomics AG issues new shares by way of private placement

Not for distribution in the United States of America

Berlin, Germany, November 7, 2016 - Epigenomics AG, Berlin, Germany
(Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the
Company is raising close to EUR 5.0 million of gross proceeds in a share
capital increase by way of private placement.

The Executive Board of Epigenomics AG, with approval of the Supervisory
Board, has today resolved on the increase of the Company's share capital in
the amount of EUR 1,035,196.00 by issuing 1,035,196 new registered shares
of the Company from the Authorized Capital 2016/I against contribution in
cash. The issue price has been set at EUR 4.83 per share.

The majority of the capital increase was subscribed by UChip Technology
Limited, a subsidiary of SummitView Capital, Shanghai (China) and the
remaining shares are the continued participation of BioChain (BVI) Inc.

The new shares will be issued by way of a private placement with the
exclusion of the shareholders' pre-emptive rights and carry dividend rights
from January 1, 2016.

Following the registration of the capital increase with the commercial
register ("Handelsregister"), the subscribed capital of Epigenomics AG will
increase from currently EUR 20,544,009.00 to EUR 21,579,205.00. Subject to
the registration of the implementation of the capital increase with the
commercial register, the admission of the new shares to the regulated
market (prime standard), of the Frankfurt Stock Exchange is expected during
November 2016. The technical implementation of the capital increase is
conducted by Bankhaus Neelmeyer, Bremen, Germany.

Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to expand its U.S commercialization capacities
for its lead product Epi proColon.

-End of Ad hoc-

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the "Shares") have not been registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act") and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.

Contact Epigenomics AG

Peter Vogt
Vice President Corporate Communications & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com
Home
--------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: Additional information: Greg Hamilton, Chief Executive Officer of Epigenomics AG, commented: 'I am very excited to welcome SummitView Capital as a new strategic investor, who has an impressive track record of investments into transformative companies. With this investment, we further strengthen our financial position, helping us in driving the commercialization of our lead product Epi proColon, the first and only FDA-approved blood-test for colorectal cancer screening.' 07.11.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Epigenomics AG Geneststraße 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A11QW50 WKN: A11QW5 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------